Wound-Healing Combo Product Jurisdiction Should Be Clarified – Ex-FDAer
This article was originally published in The Gray Sheet
The regulatory pathway for wound-healing combination products should be elucidated because they increasingly are assigned to CBER and not the device center, according to The Biologics Consulting Group Senior Consultant Darin Weber, PhD
You may also be interested in...
The Center for Biologics Evaluation & Research is flagging areas of the device review process that can be clarified through "templates" to guide staff and sponsors
Wound healing products for which a primary mode of action cannot be elucidated should remain under the jurisdiction of FDA's device center, according to Apligraf manufacturer Organogenesis
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.